These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 29946193)

  • 1. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Leopizzi M; Mundo L; Messina E; Campolo F; Lazzi S; Angeloni A; Marchese C; Leoncini L; Giordano C; Slack F; Trivedi P; Anastasiadou E
    Blood; 2024 Feb; 143(5):429-443. PubMed ID: 37847858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
    Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
    Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
    Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
    Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells.
    Yanagi Y; Okuno Y; Narita Y; Masud HMAA; Watanabe T; Sato Y; Kanda T; Kimura H; Murata T
    Virology; 2021 May; 557():44-54. PubMed ID: 33639481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
    Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 upregulation by lytic induction of Epstein-Barr Virus.
    Yanagi Y; Hara Y; Mabuchi S; Watanabe T; Sato Y; Kimura H; Murata T
    Virology; 2022 Mar; 568():31-40. PubMed ID: 35093708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
    Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
    Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M; Raithatha S; Shannon-Lowe C
    J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
    J Virol; 2020 May; 94(10):. PubMed ID: 32132242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
    Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
    Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
    Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
    Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.